Minerva Neurosciences (NASDAQ:NERV) Stock Passes Above 50-Day Moving Average – Should You Sell?

Minerva Neurosciences, Inc (NASDAQ:NERV) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $4.06 and traded as high as $4.51. Minerva Neurosciences shares last traded at $4.45, with a volume of 34,875 shares changing hands.

Wall Street Analysts Forecast Growth

NERV has been the subject of several recent research reports. HC Wainwright reduced their target price on shares of Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. Finally, Wall Street Zen lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Minerva Neurosciences presently has a consensus rating of “Reduce” and a consensus target price of $4.00.

Minerva Neurosciences Stock Down 4.1%

The business has a fifty day moving average of $4.07 and a 200 day moving average of $3.07. The firm has a market cap of $181.30 million, a P/E ratio of -2.26 and a beta of -0.28.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Research analysts expect that Minerva Neurosciences, Inc will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC boosted its position in Minerva Neurosciences, Inc (NASDAQ:NERV) by 7.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,380 shares of the biopharmaceutical company’s stock after purchasing an additional 3,066 shares during the quarter. Apella Capital LLC owned about 0.10% of Minerva Neurosciences worth $170,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.